3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
4
Leukemia
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Waldenstrom Macroglobulinemia
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Fallopian Tube Neoplasms
1
Congenital Abnormalities
1
Central Nervous System Neoplasms
1
Burkitt Lymphoma
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Irinotecan
7
Cyclophosphamide
7
Vincristine
6
Magnetic Resonance Spectroscopy
5
Dactinomycin
5
temsirolimus
4
cixutumumab
4
X-Rays
4
Sirolimus
4
Radiotherapy
4
Phantoms, Imaging
4
Etoposide
4
Doxorubicin
4
Specimen Handling
3
Radiation
3
Peripheral Blood Stem Cell Transplantation
3
Nuclear Medicine Department, Hospital
3
Melphalan
3
Ifosfamide
3
Gemcitabine
3
Filgrastim
3
ulixertinib
2
tipifarnib
2
thymoglobulin
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
larotrectinib
2
ivosidenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Rhabdomyosarcoma
×
IL32 protein, human
×
Clear all
NCT02100891
2025-03-19
STIR
Medical College of Wisconsin
Phase 2
Terminated
15 enrolled
11 charts